The observed variance between predicted and measured radiation dose in breast and prostate patients utilizing an in vivo dosimeter.

Sicel Technologies Inc., Morrisville, NC, USA.
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.52). 11/2008; 72(2):597-604. DOI: 10.1016/j.ijrobp.2008.05.058
Source: PubMed

ABSTRACT Report the results of using a permanently implantable dosimeter in radiation therapy: determine specific adverse events, degree of migration, and acquire dose measurements during treatment to determine difference between expected and measured dose.
The Dose Verification System is a wireless, permanently implantable metal-oxide semiconductor field-effect transistor dosimeter using a bidirectional antenna for power and data transfer. The study cohort includes 36 breast (33 patients received two devices) and 29 prostate (21 patients received two devices) cancer patients. A total of 1,783 and 1,749 daily dose measurements were obtained on breast and prostate patients, respectively. The measurements were compared with the planned expected dose. Biweekly computed tomography scans were obtained to evaluate migration and the National Cancer Institute's Common Toxicity Criteria, version 3, was used to evaluate adverse events.
Only Grade I/II adverse events of pain and bleeding were noted. There were only four instances of dosimeter migration of >5 mm from known factors. A deviation of > or =7% in cumulative dose was noted in 7 of 36 (19%) for breast cancer patients. In prostate cancer patients, a > or =7% deviation was noted in 6 of 29 (21%) and 8 of 19 (42%) during initial and boost irradiation, respectively. The two patterns of dose deviation were random and systematic. Some causes for these differences could involve organ movement, patient movement, or treatment plan considerations.
The Dose Verification System was not associated with significant adverse events or migration. The dosimeter can measure dose in situ on a daily basis. The accuracy and utility of the dose verification system complements current image-guided radiation therapy and intensity-modulated radiation therapy techniques.

  • [Show abstract] [Hide abstract]
    ABSTRACT: For dosimetric measurements using an implantable optical fiber probe with GaN (Gallium Nitride) scintillator as radioluminescence (RL) transducer, a bi-channel method is proposed to reject the background contribution of the irradiated fiber segment. It is based on spectral differences between the narrow-band light emission from GaN and the large-band background from the irradiated optical fiber. Experimental validation of this method using 6 MV photon beam has shown that the remaining background contribution after subtraction is below 1.2% for square field sizes ranging from 3 cm to 20 cm. Furthermore, a compensation method for the over-response of GaN is also proposed, since GaN is not tissue equivalent. The over-response factor of GaN exhibits a linear increase with square field aperture and depends on depth from phantom surface. This behaviour is modelled to allow compensation in specific conditions. The proposed method has been evaluated and has shown a maximum deviation of 3% for a 6 MV photon beam and 1% for an 18 MV photon beam at a depth beyond the build-up region.
    Physica Medica 01/2013; · 1.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In radiation therapy, the tumor and normal tissue response is highly dependent on accurate absorbed dose delivery to the intended target. Although ex vivo techniques are widely used to improve the accuracy of the dose delivered, it is impossible to verify that the dose has been delivered correctly without mea-suring the dose within the patient. The Dose Verification System (Sicel Technologies, Inc., Morrisville, NC), which consists of an im-plantable MOSFET dosimeter and a wireless reader, is currently the only commercial dosimetry system capable of measuring this in situ dose. Since the MOSFET dosimeter is implanted in the patient, it has been suggested that it could be used as not only a dosimeter but also a fiducial marker for image-guided radiation therapy (IGRT) provided that it could be seen on radiographs. Though visible on kilovoltage radiographs, the current design of the dosimeter is not visible on megavoltage radiographs limiting its usefulness in IGRT treatment. In this work, we modified the MOSFET dosimeter to increase its visibility on megavoltage radiographs. We then compared the visibility of the modified dosimeter with that of the commercial (unmodified) dosimeter and a traditional gold fiducial marker in an anthropomorphic phantom on an IGRT system. To ensure that the modification did not affect the dosimeter's ability to measure and transmit dose data, we compared the modified dosimeter's wireless read range, energy dependence, and angular dependence with those of the commercial dosimeter. We conclude that modifying the MOSFET dosimeter increased its visibility without affecting its dosimetric properties, thereby allowing a single implanted device to serve two critical roles in IGRT. Index Terms—Dose verification system, fiducial marker, image-guided radiation therapy (IGRT), in vivo dosimetry, MOSFET, quality assurance.
    IEEE Sensors Journal 01/2011; 11(10):2591-2597. · 1.85 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review evaluates example technologies from the point-of-view of likely translation into human use, including regulatory clearance, insertion into common medical practice and reimbursability. The intent is to highlight recent innovations in implantable sensors with a focus on the translational process itself in a holistic fashion. As well as looking at success stories, this review will also examine several seemingly promising technologies that have failed for reasons having nothing to do with the operational aspects of the sensors and systems involved. Innovation must be viewed as a multifaceted process, all segments of which must be fully addressed to achieve success. No party to the process can work in isolation and expect to achieve the end goal of providing new advances to patients. This review will have succeeded if it provides the reader with a better appreciation of the complex environment in which implantable sensor discoveries that seek to be translated into human medicine must navigate.
    IEEE Sensors Journal 01/2011; 11(12):3171-3182. · 1.85 Impact Factor


Available from

Similar Publications